α-突触核蛋白种子扩增试验诊断路易体痴呆:四实验室比较
该回顾性横断面研究比较了4个欧洲实验室采用不同方案对脑脊液α-突触核蛋白种子扩增试验诊断路易体痴呆的性能。纳入20例临床很可能路易体痴呆患者和10名年龄性别匹配对照,结果显示各实验室平均敏感度78.8%、特异度77.5%、准确度78.5%,但实验室间差异大且一致性仅为一般(平均κ=0.246)。
要点
- 不同实验室的α-突触核蛋白种子扩增试验方案诊断路易体痴呆的性能差异显著,敏感度55%–100%、特异度60%–100%。
- 4个实验室间结果一致性仅为一般(平均κ=0.246),提示方案标准化亟待推进。
- β-淀粉样蛋白阳性路易体痴呆患者的种子扩增试验敏感度在数值上低于阴性患者(70% vs 87.5%),但无统计学显著性。
核心结论
- 不同实验室采用的α-突触核蛋白种子扩增试验方案在诊断路易体痴呆时重复性不佳,可能阻碍其临床转化。
研究设计与样本
- 回顾性横断面研究,纳入4个欧洲实验室的数据,脑脊液样本由第五个独立实验室提供并完成统计分析。
- 纳入20例临床很可能路易体痴呆患者(平均年龄67±6岁,60%男性,多巴胺转运体显像阳性且已知β-淀粉样蛋白状态,轻中度痴呆)和10名年龄性别匹配对照(平均年龄67±2岁,70%男性)。
- 2例路易体痴呆患者有神经病理学确认。
主要发现
- 4个实验室平均敏感度78.8%(最低55%,最高100%)、特异度77.5%(最低60%,最高100%)、准确度78.5%(最低57%,最高100%)。
- 实验室A敏感度100%(CI 84%–100%)、特异度100%(CI 72%–100%);实验室B敏感度85%(CI 64%–95%)、特异度90%(CI 59%–99%)。
- 实验室C敏感度55%(CI 34%–74%)、特异度60%(CI 31%–83%);实验室D敏感度75%(CI 53%–89%)、特异度60%(CI 31%–83%)。
- β-淀粉样蛋白阳性路易体痴呆患者的种子扩增试验敏感度数值上低于β-淀粉样蛋白阴性患者(70% vs 87.5%),但无统计学显著性。
- 4个实验室间种子扩增试验结果一致性为一般(平均κ=0.246)。
临床怎么用
- 临床解读α-突触核蛋白种子扩增试验结果时需考虑实验室间方案差异对诊断性能的影响,不宜直接跨实验室套用阈值。
- 该研究支持推动种子扩增试验方案的协调与标准化,以促进其用于路易体痴呆的生物学诊断。
局限性
- 样本量小(20例路易体痴呆患者和10名对照),仅2例有神经病理学确认。
- 研究为回顾性设计,各实验室方案在α-突触核蛋白浓度和酶标仪设置上存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The α-synuclein (α-syn) seed amplification assay (SAA) has shown promising results for diagnosing dementia with Lewy bodies (DLB) using CSF samples. A barrier to implementing α-syn SAA clinically is the use of different protocols for the assay. It is unknown how different protocols perform in comparison with each other. We compared the performance of α-syn SAA across 4 laboratories using CSF samples of patients with DLB. METHODS: This was a retrospective cross-sectional study that included data from 4 different European laboratories. We included probable patients with DLB with a positive dopamine transporter (DaT)-SCAN and known amyloid-β status who had mild-to-moderate dementia, along with age-matched and sex-matched controls. The α-syn SAA was run across 4 laboratories using different protocols varying α-syn concentration and plate reader settings. CSF samples were provided by a fifth independent laboratory, which also performed statistical and result analyses. RESULTS: We included 20 patients with DLB (mean age 67 ± 6 years, 60% male) and 10 controls (mean age 67 ± 2 years, 70% male). Neuropathologic confirmation was available for 2 patients with DLB. On average, the 4 laboratories achieved 78.8% sensitivity (minimum 55%, maximum 100%), 77.5% specificity (minimum 60%, maximum 100%), and 78.5% accuracy (minimum 57%, maximum 100%) for discriminating DLB from controls, but our findings show that diagnostic performance of SAA varied across laboratories: Lab A achieved 100% sensitivity (CI 84%-100%) and 100% specificity (CI 72%-100%); Lab B achieved 85% sensitivity (CI 64%-95%) and 90% specificity (CI 59%-99%); Lab C achieved 55% sensitivity (CI 34%-74%) and 60% specificity (CI 31%-83%); and Lab D achieved 75% sensitivity (CI 53%-89%) and 60% specificity (CI 31%-83%). In general, SAA results showed numerically lower sensitivity in β-amyloid (Aβ)-positive patients with DLB (70%) compared with Aβ-negative patients with DLB (87.5%) (nonstatistically significant). A fair agreement of SAA results was obtained across the 4 laboratories (average κ = 0.246). DISCUSSION: This study highlights challenges for the reproducibility of α-syn SAA results across different protocols applied by different laboratories. This finding, together with the methodological variability reported across laboratories, may challenge the clinical implementation of the α-syn SAA. This study provides relevant support for initiating harmonization and standardization of SAA protocols to move the field toward the clinical implementation of SAAs for the biomarker-based diagnosis of DLB. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence of variations in the accuracy of CSF α-syn SAA across 4 separate laboratories in distinguishing patients with DLB from healthy controls.
引用
- Kumar R, Gravett S, Jelic V, et al. Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories. Neurology. 2026. PMID: 41604609. doi:10.1212/WNL.0000000000214614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。